Gary Middleton
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
Papers in
- Oncology 95
- Cancer Immunotherapy and Biomarkers 32
- Colorectal Cancer Treatments and Studies 28
- Pancreatic and Hepatic Oncology Research 13
- COVID-19 and healthcare impacts 10
-
- Cancer Genomics and Diagnostics 36
- Co-authors
- Leisha A. Emens (1 shared paper)David Cunningham (20 shared papers)Fareeda Y. Coxon (5 shared papers)Timothy J. Iveson (3 shared papers)Andrew Richard Norman (6 shared papers)Sheela Rao (4 shared papers)Naureen Starling (4 shared papers)Jacqueline Rose Oates (2 shared papers)
- Journals
- Annals of Oncology (20 papers)Nature (11 papers)The Lancet Oncology (11 papers)British Journal of Cancer (11 papers)Journal of Clinical Oncology (8 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
Gary Middleton
210 papers receiving 22.0k citations
Gary Middleton's Hit Papers
Peers
Comparison fields: 5 of 162
- Oncology 11.1k
- Cancer Research 4.4k
- Pulmonary and Respiratory Medicine 6.3k
- Immunology 3.1k
- Gastroenterology 634
Countries citing papers authored by Gary Middleton
This map shows the geographic impact of Gary Middleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Middleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Middleton more than expected).
Fields of papers citing papers by Gary Middleton
This network shows the impact of papers produced by Gary Middleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Middleton. The network helps show where Gary Middleton may publish in the future.
Co-authors
The 25 scholars most cited alongside Gary Middleton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 214 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer Hit paper breakdown → | 2008 | 1901 |
| 2 | Tracking the Evolution of Non–Small-Cell Lung Cancer Hit paper breakdown → | 2017 | 1770 |
| 3 | Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2017 | 1516 |
| 4 | Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution Hit paper breakdown → | 2017 | 1449 |
| 5 | Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution Hit paper breakdown → | 2017 | 1015 |
| 6 | COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Hit paper breakdown → | 2020 | 855 |
| 7 | EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 778 |
| 8 | The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies Hit paper breakdown → | 2015 | 697 |
| 9 | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial Hit paper breakdown → | 2013 | 612 |
| 10 | Lung adenocarcinoma promotion by air pollutants Hit paper breakdown → | 2023 | 528 |
| 11 | 2011 | 510 | |
| 12 | Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies Hit paper breakdown → | 2018 | 509 |
| 13 | Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer Hit paper breakdown → | 2018 | 492 |
| 14 | Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial Hit paper breakdown → | 2013 | 484 |
| 15 | COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study Hit paper breakdown → | 2020 | 443 |
| 16 | 2017 | 369 | |
| 17 | Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial Hit paper breakdown → | 2014 | 327 |
| 18 | 2011 | 319 | |
| 19 | 2013 | 318 | |
| 20 | 2017 | 283 |
About Gary Middleton
Gary Middleton is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology and Pathology and Forensic Medicine, having authored 214 papers that have together received 22.5k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (36 papers), Cancer Immunotherapy and Biomarkers (32 papers), Lung Cancer Treatments and Mutations (32 papers), Colorectal Cancer Treatments and Studies (28 papers), Pancreatic and Hepatic Oncology Research (13 papers), Immune Cell Function and Interaction (12 papers), Genetic factors in colorectal cancer (11 papers) and COVID-19 and healthcare impacts (10 papers). The work is most often cited by research in Oncology (11.1k citations), Cancer Research (4.4k citations), Pulmonary and Respiratory Medicine (6.3k citations), Immunology (3.1k citations) and Gastroenterology (634 citations). Gary Middleton has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Leisha A. Emens, David Cunningham, Fareeda Y. Coxon, Timothy J. Iveson, Andrew Richard Norman, Sheela Rao, Naureen Starling, Jacqueline Rose Oates, Francis Daniel and Marianne C. Nicolson. Their work appears in journals such as Annals of Oncology, Nature, The Lancet Oncology, British Journal of Cancer and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.